Tuning inflammation with anti-inflammatory neuropeptides

Bibliography

• MILLS KH: Regulatory T cells: friend or foe n immunity to infection? Nat. Rev. Immunol. (2004) 4:841-855.
   PubMed Web of Science ®Google Scholar
• BLUESTONE JA: Regulatory T-cell therapy: is it ready for the clinic? Nat. Rev. Immunol. (2005) 5:343-349.
   PubMed Web of Science ®Google Scholar
• SHEVACH EM: From vanilla to 28 flavors: multiple varieties of T regulatory cells. Immunity (2006) 25:195-201.
   PubMed Web of Science ®Google Scholar
• WAN YY, FAVELL RA: The roles for cytokines in the generation and maintenance of regulatory T cells. Immunol. Rev. (2006) 212:114-130.
   PubMed Web of Science ®Google Scholar
• BLALOCK JE: The immune system as the sixth sense. J. Intern. Med. (2005) 257:126-138.
   PubMed Web of Science ®Google Scholar
• STERNBERG EM: Neural regulation of innate immunity: a coordinated nonspecific host response to pathogens. Nat. Rev. Immunol. (2006) 6:318-328.
   PubMed Web of Science ®Google Scholar
• SAID SI, MUTT V: Polypeptide with broad biological activity: isolation from small intestine. Science (1970) 169:1217-1218.
   PubMed Web of Science ®Google Scholar
• HADLEY ME, HASKELL-LUEVANO C: The proopiomelanocortin system. Ann. NY Acad. Sci. (1999) 885:1-21.
   PubMed Web of Science ®Google Scholar
• OKI Y, SASANO H: Localization and physiological roles of urocortin. Peptides (2004) 25:1745-1749.
   PubMed Web of Science ®Google Scholar
• HINSON JP, KAPAS S, SMITH DM: Adrenomedullin, a multifunctional regulatory peptide. Endocr. Rev. (2000) 21:138-167.
   PubMed Web of Science ®Google Scholar
• SPIER AD, DE LECEA L: Cortistatin: a member of the somatostatin neuropeptide family with distinct physiological functions. Brain Res. Rev. (2000) 33:228-241.
   PubMed Web of Science ®Google Scholar
• VAN DER LELY AJ, TSCHOP M, HEIMAN ML, GHIGO E: Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin. Endocr. Rev. (2004) 25:426-457.
   PubMed Web of Science ®Google Scholar
• DELGADO M, POZO D, GANEA D: The significance of vasoactive intestinal peptide in immunomodulation. Pharmacol. Rev. (2004) 56:249-290.
   PubMed Web of Science ®Google Scholar
• DELGADO M, GANEA D: Cutting Edge: Is vasoactive intestinal peptide a Type 2 cytokine? J. Immunol. (2001) 166:2907-2912.
   PubMed Web of Science ®Google Scholar
• BLALOCK JE: Proopiomelanocortin and the immune-neuroendocrine connection. Ann. NY Acad. Sci. (1999) 885:161-172.
   PubMed Web of Science ®Google Scholar
• LIPTON JM, CATANIA A: Anti-inflammatory actions of the neuroimmunomodulator alpha-MSH. Immunol. Today (1997) 18:140-145.
   PubMedGoogle Scholar
• GRAVANIS A, MARGIORIS AN: The corticotropin-releasing factor (CRF) family of neuropeptides in inflammation: potential therapeutic applications. Curr. Med. Chem. (2005) 12:1503-1512.
   PubMed Web of Science ®Google Scholar
• KUBO A, MINAMINO N, ISUMI Y et al.: Production of adrenomedullin in macrophage cell line and peritoneal macrophage. J. Biol. Chem. (1998) 273:16730-16738.
   PubMed Web of Science ®Google Scholar
• DALM VA: Cortistatin rather than somatostatin as a potential endogenous ligand for somatostatin receptors in the human immune system. J. Clin. Endocrinol. Metab. (2003) 88:270-276.
   PubMed Web of Science ®Google Scholar
• POZO D: VIP- and PACAP-mediated immunomodulation as prospective therapeutic tools. Trends Mol. Med. (2003) 9:211-217.
   PubMed Web of Science ®Google Scholar
• NEUMANN ANDERSEN G, NAGAEVA O, MANDRIKA I et al.: MC(1) receptors are constitutively expressed on leucocyte subpopulations with antigen presenting and cytotoxic functions. Clin. Exp. Immunol. (2001) 126:441-446.
   PubMed Web of Science ®Google Scholar
• BECHER E, MAHNKE K, BRZOSKA T, KALDEN DH, GRABBE S, LUGER TA: Human peripheral blood-derived dendritic cells express functional melanocortin receptor MC-1R. Ann. NY Acad. Sci. (1999) 885:188-195.
   PubMed Web of Science ®Google Scholar
• TAHERZADEH S, SHARMA S, CHHAJLANI V et al.: alpha-MSH and its receptors in regulation of tumor necrosis factor-alpha production by human monocyte/macrophages. Am. J. Physiol. (1999) 276:R1289-R1294.
   PubMed Web of Science ®Google Scholar
• CATANIA A, RAJORA N, CAPSONI F, MINONZIO F, STAR RA, LIPTON JM: The neuropeptide alpha-MSH has specific receptors on neutrophils and reduces chemotaxis in vitro. Peptides (1996) 17:675-679.
   PubMed Web of Science ®Google Scholar
• GETTING SJ, GIBBS L, CLARK AJ, FLOWER RJ, PERRETTI M: POMC gene-derived peptides activate melanocortin Type 3 receptor on murine macrophages, suppress cytokine release, and inhibit neutrophil migration in acute experimental inflammation. J. Immunol. (1999) 162:7446-7453.
   PubMed Web of Science ®Google Scholar
• DALM VA: Expression of somatostatin, cortistatin, and somatostatin receptors in human monocytes, macrophages, and dendritic cells. Am. J. Physiol. Endocrinol. Metab. (2003) 285:E344-E353.
   PubMed Web of Science ®Google Scholar
• DIXIT VD, SCHAFFER EM, PYLE RS et al.: Ghrelin inhibits leptin- and activation-induced proinflammatory cytokine expression by human monocytes and T cells. J. Clin. Invest. (2004) 114:57-66.
   PubMed Web of Science ®Google Scholar
• POYNER DR, SEXTON PM, MARSHALL I et al.: International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors. Pharmacol. Rev. (2002) 54:233-246.
   PubMed Web of Science ®Google Scholar
• HAUGER RL, GRIGORIADIS DE, DALLMAN MF, PLOTSKY PM, VALE WW, DAUTZENBERG FM: International union of pharmacology. XXXVI. Current status of the nomenclature for receptors for corticotropin-releasing factor and their ligands. Pharmacol. Rev. (2003) 55:21-26.
   PubMed Web of Science ®Google Scholar
• HARMAR AJ, ARIMURA A, GOZES I et al.: International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Pharmacol. Rev. (1998) 50:265-270.
   PubMed Web of Science ®Google Scholar
• BANNER KH, TREVETHICK MA: PDE4 inhibition: a novel approach for the treatment of inflammatory bowel disease. Trends Pharmacol. Sci. (2004) 25:430-436.
   PubMed Web of Science ®Google Scholar
• LUGNIER C: Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol. Ther. (2006) 109:366-398.
   PubMed Web of Science ®Google Scholar
• GONZALEZ-REY E, CHORNY A, VARELA N, ROBLEDO G, DELGADO M: Urocortin and adrenomedullin prevent lethal endotoxemia by downregulating the inflammatory response. Am. J. Pathol. (2006) 168:1921-1930.
   PubMed Web of Science ®Google Scholar
• GONZALEZ-REY E, CHORNY A, ROBLEDO G, DELGADO M: Cortistatin, a new anti-inflammatory peptide with therapeutic action in lethal endotoxemia. J. Exp. Med. (2006) 203:463-471.
   Google Scholar
• CHIAO H, FOSTER S, THOMAS R, LIPTON J, STAR RA: Alpha-melanocyte-stimulating hormone reduces endotoxin-induced liver inflammation. J. Clin. Invest. (1996) 97:2038-2044.
   PubMed Web of Science ®Google Scholar
• DELGADO M, MARTINEZ C, POZO D et al.: Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) protect mice from lethal endotoxemia through the inhibition of TNF-α and IL-6. J. Immunol. (1999) 162:1200-1205.
   PubMed Web of Science ®Google Scholar
• WU R: Ghrelin improves tissue perfusion in severe sepsis via downregulation of endothelin-1. Cardiovasc. Res. (2005) 68:318-326.
   PubMed Web of Science ®Google Scholar
• TUNCEL N, TORE F, SAHINTURK V, AK D, TUNCEL M: Vasoactive intestinal peptide inhibits degranulation and changes granular content of mast cells: a potential therapeutic strategy in controlling septic shock. Peptides (2000) 21:81-89.
   PubMed Web of Science ®Google Scholar
• DELGADO M, ABAD C, MARTINEZ C, LECETA J, GOMARIZ RP: Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease. Nat. Med. (2001) 7:563-568.
   PubMed Web of Science ®Google Scholar
• GONZALEZ-REY E, CHORNY A, VARELA N, DEL MORAL RG, DELGADO M: Therapeutic effect of cortistatin on experimental arthritis by downregulating inflammatory and Th1 responses. Ann. Rheum. Dis. (2007) (In Press).
   Google Scholar
• CERIANI G, DIAZ J, MURPHREE S, CATANIA A, LIPTON JM: The neuropeptide alpha-melanocyte-stimulating hormone inhibits experimental arthritis in rats. Neuroimmunomodulation (1994) 1:28-32.
   PubMedGoogle Scholar
• GONZALEZ-REY E, CHORNY A, VARELA N, O’VALLE F, DELGADO M: Therapeutic effect of urocortin on collagen-induced arthritis by downregulating inflammatory and Th1 response and inducing regulatory T cells. Arthritis Rheum. (2007) 56(2):531-543.
   PubMed Web of Science ®Google Scholar
• GONZALEZ-REY E, CHORNY A, O’VALLE F, DELGADO M: Adrenomedullin protects from experimental arthritis by downregulating inflammation and Th1 response and inducing regulatory T cells. Am. J. Pathol. (2007) 170(1):263-271.
   PubMed Web of Science ®Google Scholar
• GONZALEZ-REY E, VARELA N, SHEIBANIE AF, CHORNY A, GANEA D, DELGADO M: Cortistatin, a new anti-inflammatory peptide with therapeutic action in inflammatory bowel disease. Proc. Natl. Acad. Sci. USA (2006) 103:4228-4233.
   PubMed Web of Science ®Google Scholar
• GONZALEZ-REY E, FERNANDEZ-MARTIN A, CHORNY A, DELGADO M: Therapeutic effect of urocortin and adrenomedullin in a murine model of Crohn´s disease. Gut (2006) 55:824-832.
   PubMed Web of Science ®Google Scholar
• ABAD C, MARTINEZ C, JUARRANZ MG et al.: Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn’s disease. Gastroenterology (2003) 124:961-971.
   PubMed Web of Science ®Google Scholar
• RAJORA N, BOCCOLI G, CATANIA A, LIPTON JM: alpha-MSH modulates experimental inflammatory bowel disease. Peptides (1997) 18:381-385.
   PubMed Web of Science ®Google Scholar
• GONZALEZ-REY E, CHORNY A, DELGADO M: Therapeutic action of ghrelin in a mouse model of colitis. Gastroenterology (2006) 130:1707-1720.
   PubMed Web of Science ®Google Scholar
• HERRERA JL, FERNANDEZ-MONTESINOS R, GONZALEZ-REY E, DELGADO M, POZO D: Protective role for plasmid DNA-mediated VIP gene transfer in non-obese diabetic mice. Ann. NY Acad. Sci. (2006) 1070:337-341.
   PubMed Web of Science ®Google Scholar
• ROSIGNOLI F, ROCA V, MEISS R, LECETA J, GOMARIZ RP, PEREZ LEIROS C: VIP and tolerance induction in autoimmunity. Ann. NY Acad. Sci. (2006) 1070:525-530.
   PubMed Web of Science ®Google Scholar
• POLIAK S, MOR F, CONLON P et al.: Stress and autoimmunity: the neuropeptides corticotropin-releasing factor and urocortin suppress encephalomyelitis via effects on both the hypothalamic-pituitary-adrenal axis and the immune system. J. Immunol. (1997) 158:5751-5756.
   PubMed Web of Science ®Google Scholar
• LI H, MEI Y, WANG Y, XU L: Vasoactive intestinal polypeptide suppressed experimental autoimmune encephalomyelitis by inhibiting T helper 1 responses. J. Clin. Immunol. (2006) 26:430-437.
   PubMed Web of Science ®Google Scholar
• GONZALEZ-REY E, FERNANDEZ-MARTIN A, CHORNY A et al.: Therapeutic effect of vasoactive intestinal peptide on experimental autoimmune encephalomyelitis: downregulation of inflammatory and autoimmune responses. Am. J. Pathol. (2006) 168:1179-1188.
   PubMed Web of Science ®Google Scholar
• LODDE BM, MINESHIBA F, WANG J et al.: Effect of human vasoactive intestinal peptide gene transfer in a murine model of Sjorgre’s disease. Ann. Rheum. Dis. (2006) 65:195-200.
   PubMed Web of Science ®Google Scholar
• KOJIMA M, ITO T, OONO T et al.: VIP attenuation of the severity of experimental pancreatitis is due to VPAC1 receptor-mediated inhibition of cytokine production. Pancreas (2005) 30:62-70.
   PubMed Web of Science ®Google Scholar
• DEMBINSKI A, WARZECHA Z, CERANOWICZ P et al.: Ghrelin attenuates the development of acute pancreatitis in rat. J. Physiol. Pharmacol. (2003) 54:561-573.
   PubMed Web of Science ®Google Scholar
• NISHIDA T, TAYLOR AW: Specific aqueous humor factors induce activation of regulatory T cells. Invest. Ophthalmol. Vis. Sci. (1999) 40:2268-2274.
   PubMed Web of Science ®Google Scholar
• KEINO H, KEZUKA T, TAKEUCHI M, YAMAKAWA N, HATTORI T, USUI M: Prevention of experimental autoimmune uveoretinitis by vasoactive intestinal peptide. Arch. Ophthalmol. (2004) 122:1179-1184.
   PubMed Web of Science ®Google Scholar
• DE LA FUENTE M, DELGADO M, GOMARIZ RP: VIP modulation of immune cell functions. Adv. Neuroimmunol. (1996) 6:75-91.
   PubMedGoogle Scholar
• DELGADO M, MUNOZ-ELIAS EJ, GOMARIZ RP, GANEA D: VIP and PACAP inhibit IL-12 production in LPS-stimulated macrophages. Subsequent effect on IFNγ synthesis by T cells. J. Neuroimmunol. (1999) 96:167-181.
   PubMed Web of Science ®Google Scholar
• HERNANZ A, TATO E, DE LA FUENTE M, DE MIGUEL E, ARNALICH F: Differential effects of gastrin-releasing peptide, neuropeptide Y, somatostatin and vasoactive intestinal peptide on interleukin-1 beta, interleukin-6 and tumor necrosis factor-alpha production by whole blood cells from healthy young and old subjects. J. Neuroimmunol. (1997) 71:25-30.
   Web of Science ®Google Scholar
• DELGADO M, POZO D, MARTINEZ C et al.: Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit endotoxin-induced TNF production by macrophages: in vitro and in vivo studies. J. Immunol. (1999) 162:2358-2367.
   PubMed Web of Science ®Google Scholar
• DELGADO R, CARLIN A, AIRAGHI L et al.: Melanocortin peptides inhibit production of proinflammatory cytokines and nitric oxide by activated microglia. J. Leukoc. Biol. (1998) 63:740-745.
   PubMed Web of Science ®Google Scholar
• DELGADO M, JONAKAIT GM, GANEA D: Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit chemokine production in activated microglia. Glia (2002) 39:148-161.
   PubMed Web of Science ®Google Scholar
• DELGADO M, LECETA J, GANEA D: Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit the production of proinflammatory mediators by activated microglia by downregulating NFkB. J. Leukoc. Biol. (2003) 73:155-164.
   PubMed Web of Science ®Google Scholar
• MARTINEZ C, DELGADO M, POZO D et al.: Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide modulate endotoxin-induced IL-6 production by murine peritoneal macrophages. J. Leukoc. Biol. (1998) 63:591-601.
   PubMed Web of Science ®Google Scholar
• DELGADO M, MUÑOZ-ELÍAS EJ, GOMARIZ RP, GANEA D: Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide prevent inducible nitric oxide synthase transcription in macrophages by inhibiting NF-kB and IFN regulatory factor 1 activation. J. Immunol. (1999) 162:4685-4696.
   PubMed Web of Science ®Google Scholar
• AGNELLO D, BERTINI R, SACCO S, MEAZZA C, VILLA P, GHEZZI P: Corticosteroid-independent inhibition of tumor necrosis factor production by the neuropeptide urocortin. Am. J. Physiol. Endocrinol. Metab. (1998) 275:E757-E762.
   Web of Science ®Google Scholar
• DELGADO M, GANEA D: Inhibition of endotoxin-induced macrophage chemokine production by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in vitro and in vivo. J. Immunol. (2001) 167:966-975.
   PubMed Web of Science ®Google Scholar
• BHARDWAJ RS, SCHWARZ A, BECHER E et al.: Pro-opiomelanocortin-derived peptides induce IL-10 production in human monocytes. J. Immunol. (1996) 156:2517-2521.
   PubMed Web of Science ®Google Scholar
• DELGADO M, MUÑOZ-ELÍAS EJ, GOMARIZ RP, GANEA D: Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies. J. Immunol. (1999) 162:1707-1716.
   PubMed Web of Science ®Google Scholar
• LUGER TA, SCHOLZEN TE, BRZOSKA T, BOHM M: New insights into the functions of alpha-MSH and related peptides in the immune system. Ann. NY Acad. Sci. (2003) 994:133-140.
   PubMed Web of Science ®Google Scholar
• DELGADO M, REDUTA A, SHARMA V, GANEA D: VIP/PACAP oppositely affect immature and mature dendritic cell expression of CD80/CD86 and the stimulatory activity of CD4+ T cells. J. Leukoc. Biol. (2004) 75:1122-1130.
   PubMed Web of Science ®Google Scholar
• GOMARIZ RP, ARRANZ A, ABAD C et al.: Time-course expression of Toll-like receptors 2 and 4 in inflammatory bowel disease and homeostatic effect of VIP. J. Leukoc. Biol. (2005) 78:491-502.
   PubMed Web of Science ®Google Scholar
• SARKAR A, SREENIVASAN Y, MANNA SK: alpha-Melanocyte-stimulating hormone inhibits lipopolysaccharide-induced biological responses by downregulating CD14 from macrophages. FEBS Lett. (2003) 553:286-294.
   PubMed Web of Science ®Google Scholar
• DELGADO M, LECETA J, ABAD C, MARTINEZ C, GANEA D, GOMARIZ RP: Shedding of membrane-bound CD14 from lipopolysaccharide-stimulated macrophages by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. J. Neuroimmunol. (1999) 99:61-71.
   PubMed Web of Science ®Google Scholar
• TSATSANIS C, ANDROULIDAKI A, DERMITZAKI E et al.: Urocortin 1 and urocortin 2 induce macrophage apoptosis via CRFR2. FEBS Lett. (2005) 579:4259-4264.
   PubMed Web of Science ®Google Scholar
• DELGADO M, LECETA J, GOMARIZ RP, GANEA D: VIP and PACAP stimulate the induction of Th2 responses by upregulating B7.2 expression. J. Immunol. (1999) 163:3629-3635.
   PubMed Web of Science ®Google Scholar
• DELGADO M, GONZALEZ-REY E, GANEA D: VIP/PACAP preferentially attract Th2 versus Th1 cells by differentially regulating the production of chemokines by dendritic cells. FASEB J. (2004) 18:1453-1455.
   PubMed Web of Science ®Google Scholar
• DELGADO M, LECETA J, GANEA D: Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide promote in vivo generation of memory Th2 cells. FASEB J. (2002) 16:1844-1846.
   PubMed Web of Science ®Google Scholar
• VOICE J, DONNELLY S, DORSAM G, DOLGANOV G, PAUL S, GOETZL EJ: c-Maf and JunB mediation of Th2 differentiation induced by the Type 2 G protein-coupled receptor (VPAC2) for vasoactive intestinal peptide. J. Immunol. (2004) 172:7289-7296.
   PubMed Web of Science ®Google Scholar
• FERNANDEZ-MARTIN A, GONZALEZ-REY E, CHORNY A, GANEA D, DELGADO M: Vasoactive intestinal peptide induces regulatory T cells during experimental autoimmune encephalomyelitis. Eur. J. Immunol. (2006) 36:318-326.
   PubMed Web of Science ®Google Scholar
• GONZALEZ-REY E, FERNANDEZ-MARTIN A, CHORNY A, DELGADO M: Vasoactive intestinal peptide induces CD4+CD25+ regulatory T cells with therapeutic effect on collagen-induced arthritis. Arthritis Rheum. (2006) 54:864-876.
   PubMed Web of Science ®Google Scholar
• CHORNY A, GONZALEZ-REY E, FERNANDEZ-MARTIN A, POZO D, GANEA D, DELGADO M: Vasoactive intestinal peptide induces regulatory dendritic cells with therapeutic effects on autoimmune disorders. Proc. Natl. Acad. Sci. USA (2005) 102:13562-13567.
   PubMed Web of Science ®Google Scholar
• CASTRO A, JEREZ MJ, GIL C, MARTINEZ A: Cyclic nucleotide phosphodiesterases and their role in immunomodulatory responses: advances in the development of specific phosphodiesterase inhibitors. Med. Res. Rev. (2005) 25:229-244.
   PubMed Web of Science ®Google Scholar
• YOON SW, GOH SH, CHUN JS et al.: alpha-Melanocyte-stimulating hormone inhibits lipopolysaccharide-induced tumor necrosis factor-alpha production in leukocytes by modulating protein kinase A, p38 kinase, and nuclear factor kappa B signaling pathways. J. Biol. Chem. (2003) 278:32914-32920.
   PubMed Web of Science ®Google Scholar
• DELGADO M, GANEA D: Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit nuclear factor-kappaB-dependent gene activation at multiple levels in the human monocytic cell line THP-1. J. Biol. Chem. (2001) 276:369-380.
   PubMed Web of Science ®Google Scholar
• DELGADO M, GANEA D: Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide inhibit the MEKK1/MEK4/JNK signaling pathway in LPS-stimulated macrophages. J. Neuroimmunol. (2000) 110:97-105.
   PubMed Web of Science ®Google Scholar
• DELGADO M, GANEA D: Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit interleukin-12 transcription by regulating nuclear factor kappaB and Ets activation. J. Biol. Chem. (1999) 274:31930-31940.
   PubMed Web of Science ®Google Scholar
• DELGADO M, GANEA D: Inhibition of IFN-gamma-induced janus kinase-1-STAT1 activation in macrophages by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. J. Immunol. (2000) 165:3051-3057.
   PubMed Web of Science ®Google Scholar
• DELGADO M: Inhibition of interferon (IFN) gamma-induced Jak-STAT1 activation in microglia by vasoactive intestinal peptide: inhibitory effect on CD40, IFN-induced protein-10, and inducible nitric-oxide synthase expression. J. Biol. Chem. (2003) 278:27620-27629.
   PubMed Web of Science ®Google Scholar
• TAYLOR AW: The immunomodulating neuropeptide alpha-melanocyte-stimulating hormone (α-MSH) suppresses LPS-stimulated TLR4 with IRAK-M in macrophages. J. Neuroimmunol. (2005) 162:43-50.
   PubMed Web of Science ®Google Scholar
• JUARRANZ Y, ABAD C, MARTINEZ C et al.: Protective effect of vasoactive intestinal peptide on bone destruction in the collagen-induced arthritis model of rheumatoid arthritis. Arthritis Res. Ther. (2005) 7:1034-1045.
   Google Scholar
• YIN H, CHENG H, YU M et al.: Vasoactive intestinal peptide ameliorates synovial cell functions of collagen-induced arthritis rats by down-regulating NF-kappaB activity. Immunol. Invest. (2005) 34:153-169.
   PubMed Web of Science ®Google Scholar
• LI WG, GAVRILA D, LIU X et al.: Ghrelin inhibits proinflammatory responses and nuclear factor-kappaB activation in human endothelial cells. Circulation (2004) 109:2221-2226.
   PubMed Web of Science ®Google Scholar
• KONTUREK PC, BRZOZOWSKI T, WALTER B et al.: Ghrelin-induced gastroprotection against ischemia-reperfusion injury involves an activation of sensory afferent nerves and hyperemia mediated by nitric oxide. Eur. J. Pharmacol. (2006) 536:171-181.
   PubMed Web of Science ®Google Scholar
• PLEGUEZUELOS O, KAPAS S: Differentiation of the HaCaT keratinocyte cell line: modulation by adrenomedullin. Br. J. Dermatol. (2006) 154:602-608.
   PubMed Web of Science ®Google Scholar
• KATO K, YIN H, AGATA J, YOSHIDA H, CHAO L, CHAO J: Adrenomedullin gene delivery attenuates myocardial infarction and apoptosis after ischemia and reperfusion. Am. J. Physiol. Heart Circ. Physiol. (2003) 285:H1506-H1514.
   PubMed Web of Science ®Google Scholar
• SASHINAMI H, KAGEYAMA K, SUDA T, NAKANE A: Urocortin 2 suppresses host resistance to Listeria monocytogenes infection via up-regulation of interleukin-10. Endocrinology (2005) 146:5003-5011.
   PubMed Web of Science ®Google Scholar
• CHATZAKI E, CHARALAMPOPOULOS I, LEONTIDIS C et al.: Urocortin in human gastric mucosa: relationship to inflammatory activity. J. Clin. Endocrinol. Metab. (2003) 88:478-483.
   PubMed Web of Science ®Google Scholar
• PUNN A, LEVINE MA, GRAMMATOPOULOS DK: Identification of signaling molecules mediating corticotropin-releasing hormone-R1α-mitogen-activated protein kinase (MAPK) interactions: the critical role of phosphatidylinositol 3-kinase in regulating ERK1/2 but not p38 MAPK activation. Mol. Endocrinol. (2006) 20:3179-3195.
   PubMed Web of Science ®Google Scholar
• MOFFATT JD, LEVER R, PAGE CP: Activation of corticotropin-releasing factor receptor-2 causes bronchorelaxation and inhibits pulmonary inflammation in mice. FASEB J. (2006) 20:1877-1879.
   PubMed Web of Science ®Google Scholar
• KOKKOTOU E, TORRES D, MOSS AC et al.: Corticotropin-releasing hormone receptor 2-deficient mice have reduced intestinal inflammatory responses. J. Immunol. (2006) 177:3355-3361.
   PubMed Web of Science ®Google Scholar
• LA FLEUR SE, WICK EC, IDUMALLA PS, GRADY EF, BHARGAVA A: Role of peripheral corticotropin-releasing factor and urocortin II in intestinal inflammation and motility in terminal ileum. Proc. Natl. Acad. Sci. USA (2005) 102:7647-7652.
   PubMed Web of Science ®Google Scholar
• BRAIN SD, GRANT AD: Vascular actions of calcitonin gene-related peptide and adrenomedullin. Physiol. Rev. (2004) 84:903-934.
   PubMed Web of Science ®Google Scholar
• ELSASSER TH, KAHL S: Adrenomedullin has multiple roles in disease stress: development and remission of the inflammatory response. Microsc. Res. Techn. (2002) 57:120-129.
   PubMed Web of Science ®Google Scholar
• PIO R, MARTINEZ A, UNSWORTH EJ et al.: Complement factor H is a serum-binding protein for adrenomedullin, and the resulting complex modulates the bioactivities of both partners. J. Biol. Chem. (2001) 276:12292-12300.
   PubMed Web of Science ®Google Scholar
• WU R, ZHOU M, WANG P: Adrenomedullin and adrenomedullin binding protein-1 downregulate TNFα in macrophage cell line and rat Kupffer cells. Regul. Pept. (2003) 112:19-26.
   PubMed Web of Science ®Google Scholar
• DEGHENGHI R, PAPOTTI M, GHIGO E, MUCCIOLI G: Cortistatin, but not somatostatin, binds to growth hormone secretagogue (GHS) receptors of human pituitary gland. J. Endocrinol. Invest. (2001) 24:RC1-RC3.
   PubMed Web of Science ®Google Scholar
• UEDA S, NISHIO K, MINAMINO N et al.: Increased plasma levels of adrenomedullin in patients with systemic inflammatory response syndrome. Am. J. Respir. Crit. Care Med. (1999) 160:132-136.
   PubMed Web of Science ®Google Scholar
• BRANDTZAEG P, OKTEDALEN O, KIERULF P, OPSTAD PK: Elevated VIP and endotoxin plasma levels in human Gram-negative septic shock. Regul. Pept. (1989) 24:37-44.
   PubMed Web of Science ®Google Scholar
• DELGADO M, ABAD C, MARTINEZ C et al.: Vasoactive intestinal peptide in the immune system: potential therapeutic role in inflammatory and autoimmune diseases. J. Mol. Med. (2002) 80:16-24.
   PubMed Web of Science ®Google Scholar
• YUDOH K, MATSUNO H, KIMURA T: Plasma adrenomedullin in rheumatoid arthritis compared with other rheumatic diseases. Arthritis Rheum. (1999) 42:1297-1298.
   PubMed Web of Science ®Google Scholar
• TORPY DJ, WEBSTER EL, ZACHMAN EK et al.: Urocortin and inflammation: confounding effects of hypotension on measures of inflammation. Neuroimmunomodulation (1999) 6:182-186.
   PubMed Web of Science ®Google Scholar
• PERACCHI M, BARDELLA MT, CAPRIOLI F et al.: Circulating ghrelin levels in patients with inflammatory bowel disease. Gut (2006) 55:432-433.
   PubMed Web of Science ®Google Scholar
• CUTULI M, CRISTIANI S, LIPTON JM, CATANIA A: Antimicrobial effects of alpha-MSH peptides. J. Leukoc. Biol. (2000) 67:233-239.
   PubMed Web of Science ®Google Scholar
• ALLAKER RP, ZIHNI C, KAPAS S: An investigation into the antimicrobial effects of adrenomedullin on members of the skin, oral, respiratory tract and gut microflora. FEMS Immunol. Med. Microbiol. (1999) 23:289-293.
   PubMed Web of Science ®Google Scholar
• MARTINEZ C, ABAD C, DELGADO M et al.: Anti-inflammatory role in septic shock of pituitary adenylate cyclase-activating polypeptide receptor. Proc. Natl. Acad. Sci. USA (2002) 99:1053-1058.
   PubMed Web of Science ®Google Scholar
• SZEMA AM, HAMIDI SA, LYUBSKY S et al.: Mice lacking the VIP gene show airway hyperresponsiveness and airway inflammation, partially reversible by VIP. Am. J. Physiol. Lung Cell. Mol. Physiol. (2006) 291:880-886.
   PubMed Web of Science ®Google Scholar
• VOICE JK, DORSAM G, LEE H, KONG Y, GOETZL EJ: Allergic diathesis in transgenic mice with constitutive T cell expression of inducible VIP receptor. FASEB J. (2001) 15:2489-2496.
   PubMed Web of Science ®Google Scholar
• GOETZL EJ, VOICE JK, SHEN S et al.: Enhanced delayed-type hypersensitivity and diminished immediate type hypersensitivity in mice lacking the inducible VPAC(2) receptor for VIP. Proc. Natl. Acad. Sci. USA (2001) 98:13854-13859.
   PubMed Web of Science ®Google Scholar
• VOICE JK, GRINNINGER C, KONG Y, BANGALE Y, PAUL S, GOETZL EJ: Roles of vasoactive intestinal peptide (VIP) in the expression of different immune phenotypes by wild-type mice and T cell-targeted Type II VIP receptor transgenic mice. J. Immunol. (2003) 170:308-314.
   PubMed Web of Science ®Google Scholar
• NAGAYA N, SATOH T, NISHIKIMI T et al.: Hemodynamic, renal, and hormonal effects of adrenomedullin infusion in patients with congestive heart failure. Circulation (2000) 101:498-503.
   PubMed Web of Science ®Google Scholar
• DAVIS ME, PEMBERTON CJ, YANDLE TG et al.: Effect of urocortin 1 infusion in humans with stable congestive cardiac failure. Clin. Sci. (2005) 109:381-388.
   PubMed Web of Science ®Google Scholar
• PETKOV V, MOSGOELLER W, ZIESCHE R et al.: Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J. Clin. Invest. (2003) 111:1339-1146.
   PubMed Web of Science ®Google Scholar
• BROGLIO F, KOETSVELD PV, BENSO A et al.: Ghrelin secretion is inhibited by either somatostatin or cortistatin in humans. J. Clin. Endocrinol. Metab. (2002) 87:4829-4832.
   PubMed Web of Science ®Google Scholar
• AROSIO M, RONCHI CL, GEBBIA C et al.: Ghrelin administration affects circulating pituitary and gastro-entero-pancreatic hormones in acromegaly. Eur. J. Endocrinol. (2004) 150:27-32.
   PubMed Web of Science ®Google Scholar
• DELGADO M, GANEA D: Vasoactive intestinal peptide prevents activated microglia-induced neurodegeneration under inflammatory conditions: potential therapeutic role in brain trauma. FASEB J. (2003) 17:1922-1924.
   PubMed Web of Science ®Google Scholar
• DELGADO M, GANEA D: Neuroprotective effect of vasoactive intestinal peptide (VIP) in a mouse model of Parkinson’s disease by blocking microglial activation. FASEB J. (2003) 17:944-946.
   PubMed Web of Science ®Google Scholar
• MUCENIECE R, ZVEJNIECE L, LIEPINSH E et al.: The MC3 receptor binding affinity of melanocortins correlates with the nitric oxide production inhibition in mice brain inflammation model. Peptides (2006) 27:1443-1450.
   PubMed Web of Science ®Google Scholar
• GIULIANI D, MIONI C, ALTAVILLA D et al.: Both early and delayed treatment with melanocortin 4 receptor-stimulating melanocortins produces neuroprotection in cerebral ischemia. Endocrinology (2006) 147:1126-1135.
   PubMed Web of Science ®Google Scholar
• ONYUKSEL H, IKEZAKI H, PATEL M, GAO XP, RUBINSTEIN I: A novel formulation of VIP in sterically stabilized micelles amplifies vasodilation in vivo. Pharm. Res. (1999) 16:155-160.
   PubMed Web of Science ®Google Scholar
• FOEY AD, FIELD S, AHMED S et al.: Impact of VIP and cAMP on the regulation of TNF-alpha and IL-10 production: implications for rheumatoid arthritis. Arthritis Res. Ther. (2003) 5:317-328.
   Google Scholar
• WECKBECKER G, LEWIS I, ALBERT R, SCHMID HA, HOYER D, BRUNS C: Opportunities in somatostatin research: biological, chemical and therapeutic aspects. Nat. Rev. Drug Discov. (2003) 2:999-1017.
   PubMed Web of Science ®Google Scholar
• GONZALEZ-REY E, CHORNY A, DELGADO M: Regulation of immune tolerance by anti-inflammatory neuropeptides. Nat. Rev. Immunol. (2007) 7:53-63.
   Google Scholar